TIDMDDDD
RNS Number : 2509X
4d Pharma PLC
04 January 2022
4D pharma appoints John Doyle as Chief Financial Officer
Leeds, UK, January 4, 2022 , - 4D pharma plc (AIM: DDDD, NASDAQ:
LBPS), a pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs), a novel class of drug derived from
the microbiome, today announces the appointment of John Doyle as
Chief Financial Officer (CFO) and member of the Company's
management team. Mr. Doyle brings over 15 years of experience
leading and developing the financial operations, strategy, and
investor relations functions at public healthcare companies.
"We are delighted to welcome John to 4D pharma at this exciting
stage of the company's growth, following our NASDAQ listing in
2021," said Duncan Peyton, Chief Executive Officer of 4D pharma.
"John's extensive financial experience in diverse healthcare
organizations and transformational events will be invaluable as 4D
pharma continues to make progress in the clinic on multiple fronts
with our Live Biotherapeutic programs."
"I am honored to join a company that is committed to deliver a
revolutionary class of medicines by harnessing bacteria from the
microbiome, said John Doyle, Chief Financial Officer of 4D pharma.
"The 4D pharma team has built an impressive pipeline across key
areas of high unmet need and I am excited for the opportunity to
execute on the company's growth strategy and financial goals ."
Mr. Doyle joins 4D pharma after serving as CFO at Chiasma Inc.,
a publicly traded biopharmaceutical company acquired by Amryt
Pharma in 2021. Prior to Chiasma, John was Vice President of
Finance and Investor Relations at Verastem Inc., a publicly traded
biopharmaceutical company. Prior to joining Verastem in February
2018, he served as Head of Financial Planning & Analysis at
SimpliVity Corp., a software company that was acquired by Hewlett
Packard Enterprises in February 2017. Before that, Mr. Doyle was
Director of Business Unit Financial Planning & Analysis, Early
Phase Division, at PAREXEL, a publicly traded pharmaceutical
contract research organization. Earlier in his career, he served in
increasingly senior financial planning and analysis roles at
Hologic, Inc., a publicly traded provider of medical diagnostic,
surgical and imaging products. Mr. Doyle holds a B.S. in finance
from the University of Massachusetts.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx(R), that rationally identifies Live Biotherapeutics based
on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has five clinical programs,
namely a Phase I/II study of MRx0518 in combination with
KEYTRUDA(R) (pembrolizumab) in solid tumors, a Phase I study of
MRx0518 in a neoadjuvant setting for patients with solid tumors, a
Phase I study of MRx0518 in patients with pancreatic cancer, a
Phase I/II study of MRx-4DP0004 in asthma, and Blautix(R) in
Irritable Bowel Syndrome (IBS) which has completed a successful
Phase II trial. Preclinical-stage programs include candidates for
CNS disease such as Parkinson's disease and other neurodegenerative
conditions. The Company has a research collaboration with MSD, a
tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to
discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
Contact Information:
4D pharma
Investor Relations: ir@4dpharmaplc.com
Singer Capital Markets - Nominated Adviser and Joint Broker +44
(0)20 7496 3000
Philip Davies / James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500
Dominic Wilson
Stern Investor Relations, Inc. +1-212-362-1200
Julie Seidel Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685
Neil Hunter / Michelle Boxall
neil@ibcomms.agency / michelle@ibcomms.agency
6 Degrees
Lynne Dardanell +1-336-202-9689
ldardanell@6degreespr.com
Forward-Looking Statements
This announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this announcement, including without limitation statements
regarding the efficacy of Live Biotherapeutics including Blautix(R)
, its ability to impact the treatment of irritable bowel syndrome,
regulatory interactions, and the utility of the MicroRx(R) and
MicroDx(R) platforms are forward-looking statements within the
meaning of Section 27A of the United States Securities Act of 1933,
as amended (the "Securities Act"), and Section 21E of the United
States Securities Exchange Act of 1934, as amended (the "Exchange
Act"). Forward-looking statements are often identified by the words
"believe," "expect," "anticipate," "plan," "intend," "foresee,"
"should," "would," "could," "may," "estimate," "outlook" and
similar expressions, including the negative thereof. The absence of
these words, however, does not mean that the statements are not
forward-looking. These forward-looking statements are based on the
Company's current expectations, beliefs and assumptions concerning
future developments and business conditions and their potential
effect on the Company. While management believes that these
forward-looking statements are reasonable as and when made, there
can be no assurance that future developments affecting the Company
will be those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties, some of which are significant
or beyond its control, and assumptions that could cause actual
results to differ materially from the Company's historical
experience and its present expectations or projections. The
foregoing factors and the other risks and uncertainties that affect
the Company's business, including the risks relating to the
activity and efficacy of its Live Biotherapeutic drug candidates
including Blautix, interactions with regulatory bodies including
the US FDA, and those additional risks and uncertainties described
the documents filed by the Company with the US Securities and
Exchange Commission ("SEC"), should be carefully considered. The
Company wishes to caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date hereof.
The Company undertakes no obligation to publicly update or revise
any of its forward-looking statements after the date they are made,
whether as a result of new information, future events or otherwise,
except to the extent required by law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABJMMTMTBMTAT
(END) Dow Jones Newswires
January 04, 2022 02:00 ET (07:00 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024